The pathogenic events in multiple sclerosis (MS) that result in immune cell infiltration,
multifocal demyelination and axonal loss have been focused by the strong impact of the …

Bevacizumab is a full-length, humanized monoclonal antibody directed against all the
biologically active isoforms of vascular endothelial growth factor (VEGF-A). The antibody …

Purpose Intravitreal injection of VEGF inhibitors has become the standard of care for
different macular diseases within the last years resulting in improved visual outcomes …

The intravitreal delivery of therapeutic agents promises major benefits in the field of ocular
medicine. Traditional delivery methods rely on the random, passive diffusion of molecules …

purpose. The penetration of intravitreally injected bevacizumab in its commercial formulation
(Avastin; Roche, Grenzach, Germany) through the retina was studied, to determine whether …

Background The human monoclonal antibody opicinumab (BIIB033, anti-LINGO-1) has
shown remyelinating activity in preclinical studies. We therefore assessed the safety and …

PURPOSE: To determine whether intracameral bevacizumab decreases vascular leakage
from iris rubeosis in patients with neovascular glaucoma. DESIGN: Interventional case …

PURPOSE: To examine the ultrastructural effect of intravitreal bevacizumab on primate eyes
with particular focus set on the choriocapillaris and to examine the influence of vascular …

Purpose: That vascular endothelial growth factor (VEGF) plays a major role in inflammatory
angiogenesis has been well established. This pilot study was designed to evaluate …

PURPOSE: To investigate the vitreous levels of bevacizumab and vascular endothelial
growth factor-A (VEGF-A) after intravitreal injection of the drug in patients with choroidal …